Zhao, Boyang http://orcid.org/0000-0003-4610-1707
Rao, Yiyun
Leighow, Scott
O’Brien, Edward P. http://orcid.org/0000-0001-9809-3273
Gilbert, Luke http://orcid.org/0000-0001-5854-0825
Pritchard, Justin R. http://orcid.org/0000-0001-7749-4473
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R21EB026617)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1U01CA265709)
National Science Foundation (NSF CBET 2033673)
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (DP2 CA239597)
Article History
Received: 24 February 2021
Accepted: 23 December 2021
First Online: 2 February 2022
Competing interests
: J.R.P. consults for Theseus Pharmaceuticals, MOMA Therapeutics, Takeda Pharmaceuticals, and Third Rock Ventures. J.R.P. has an ownership interest in Theseus Pharmaceuticals and MOMA Therapeutics. J.R.P. is a cofounder of Theseus Pharmaceuticals. B.Z. is the owner of Quantalarity Research Group. L.A.G. is a cofounder of Chroma Medicine, who has filed patents on CRISPR functional genomics that include: (1) optimized small guide RNAs and methods of use, PCT/US2014/058133, US Patent 10,822,606; (2) CRISPR/Cas Transcriptional Modulation, PCT/US2015/040449, patent pending; (3) compositions and methods for CRISPR-based screening, PCT/US2017/066842. The remaining authors declare no competing interests.